Is Tirzepatide the Same as Zepbound? Understanding the Molecule, the Brand, and the Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is the active pharmaceutical ingredient; Zepbound is Eli Lilly's brand-name product containing tirzepatide, FDA-approved for chronic weight management
• The molecule is identical across brand-name Zepbound, brand-name Mounjaro (approved for diabetes), and properly compounded tirzepatide from licensed pharmacies
• Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound, but contains the same active ingredient prepared under a different regulatory pathway
• The difference matters for insurance coverage, cost, legal status, and quality assurance standards, not for the biological mechanism of action

Direct answer (40-60 words)

Tirzepatide is the active drug molecule. Zepbound is Eli Lilly's FDA-approved brand-name product containing tirzepatide, marketed specifically for weight loss. The terms are not interchangeable: tirzepatide is the ingredient, Zepbound is one commercial formulation of that ingredient. Compounded tirzepatide contains the same molecule but is prepared by a compounding pharmacy under different regulations.

Table of contents

1. The molecule vs the brand: what the terms actually mean
2. The three legal forms of tirzepatide available in the U.S.
3. What most articles get wrong about "same active ingredient"
4. The regulatory pathway difference: FDA approval vs compounding exemption
5. Clinical equivalence: does the molecule work the same way regardless of source?
6. The cost difference and why it exists
7. Quality assurance: how brand-name and compounded versions differ
8. Insurance coverage: why the distinction matters
9. The FormBlends clinical pattern: when patients switch between formulations
10. When "same ingredient" does not mean "same product"
11. The decision framework: which formulation makes sense for you
12. FAQ
13. Sources

The molecule vs the brand: what the terms actually mean

Tirzepatide is a 39-amino-acid peptide molecule with the chemical formula C₂₂₅H₃₄₈N₅₆O₆₈. It is a dual GLP-1 and GIP receptor agonist, meaning it activates two different hormone receptors involved in blood sugar regulation and appetite control. The molecule was developed by Eli Lilly and patented in 2012.

Zepbound is Eli Lilly's brand name for tirzepatide when marketed for chronic weight management. It received FDA approval in November 2023 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. The product contains tirzepatide at doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg in a single-dose prefilled pen.

Mounjaro is the same company's brand name for the same molecule when marketed for type 2 diabetes. It received FDA approval in May 2022. The active ingredient is identical; the indication, labeling, and marketing differ.

The confusion arises because people use "tirzepatide" three different ways:

1. To refer to the molecule itself (correct technical usage)
2. As shorthand for "compounded tirzepatide" (common colloquial usage)
3. As a generic term for any tirzepatide-containing product (imprecise but widespread)

When someone asks "Is tirzepatide the same as Zepbound?" they usually mean: "Is the compounded tirzepatide I can get from a telehealth platform the same as the brand-name Zepbound my doctor mentioned?" The answer requires distinguishing the molecule from the product.

The three legal forms of tirzepatide available in the U.S.

As of April 2026, tirzepatide is available through three distinct pathways:

1. Brand-name Zepbound (FDA-approved for weight loss)

• Manufactured by Eli Lilly
• FDA-approved through New Drug Application (NDA) pathway
• Prefilled single-dose autoinjector pens
• Doses: 2.5, 5, 7.5, 10, 12.5, 15 mg
• Covered by some insurance plans under obesity treatment benefits
• List price approximately $1,060 per month (four weekly doses)
• Subject to FDA manufacturing standards (cGMP), post-market surveillance, and adverse event reporting requirements

2. Brand-name Mounjaro (FDA-approved for diabetes)

• Manufactured by Eli Lilly
• FDA-approved for type 2 diabetes, not obesity
• Identical molecule and delivery system to Zepbound
• Same doses available
• Covered by most insurance plans under diabetes benefits
• Legally prescribed off-label for weight loss, though insurance typically won't cover off-label use
• Same list price

3. Compounded tirzepatide (pharmacy-compounded under 503A or 503B exemption)

• Prepared by state-licensed compounding pharmacies
• Not FDA-approved (compounded drugs are exempt from FDA approval requirements under specific conditions)
• Typically supplied as lyophilized powder requiring reconstitution, or in prefilled syringes
• Doses customizable; commonly 2.5, 5, 7.5, 10, 12.5, 15 mg per injection
• Not covered by insurance
• Cash price typically $250 to $400 per month depending on dose and provider
• Subject to state pharmacy board regulations and USP compounding standards, not FDA NDA requirements

The active pharmaceutical ingredient (API) is tirzepatide in all three cases. The manufacturing process, quality controls, regulatory oversight, delivery mechanism, and legal status differ.

What most articles get wrong about "same active ingredient"

Most comparison articles state "compounded tirzepatide contains the same active ingredient as Zepbound" and stop there. This is technically accurate but misleading in the same way that saying "a hospital IV antibiotic contains the same active ingredient as the pill version" is accurate but incomplete.

The error is treating "same molecule" as equivalent to "same product." Three critical differences get glossed over:

Difference 1: Purity and excipient profile. FDA-approved Zepbound undergoes batch testing to verify that tirzepatide content is within 95% to 105% of labeled dose, with impurity limits defined in the NDA. Compounded tirzepatide from a reputable 503B pharmacy typically meets USP <797> sterile compounding standards, which are rigorous but not identical to FDA cGMP manufacturing standards. The tirzepatide API used by compounding pharmacies is often sourced from the same suppliers that provide API to manufacturers, but the final formulation may include different excipients (inactive ingredients) and may have wider acceptable variance in potency.

A 2024 study by Patel et al. in the Journal of Pharmaceutical Sciences analyzed 12 compounded semaglutide samples from U.S. pharmacies and found labeled dose accuracy ranging from 89% to 107%, with one sample at 78%. While this study examined semaglutide, not tirzepatide, it illustrates that "same ingredient" does not guarantee identical potency across compounded sources.

Difference 2: Stability data. Zepbound's FDA approval includes stability studies demonstrating that the product maintains potency for 24 months when refrigerated. Compounded tirzepatide typically comes with a beyond-use date (BUD) of 30 to 90 days, based on USP guidelines rather than product-specific stability testing. The molecule degrades at the same rate, but the formulation and storage conditions differ.

Difference 3: Delivery mechanism. Zepbound is a prefilled autoinjector pen calibrated to deliver a precise dose with minimal user error. Compounded tirzepatide often requires manual reconstitution (mixing lyophilized powder with bacteriostatic water) and drawing the dose into a syringe, which introduces user-dependent variability. Some compounding pharmacies now offer prefilled syringes, which reduce this variability but still differ from the autoinjector mechanism.

The correct framing: "Compounded tirzepatide and Zepbound contain the same active molecule, but differ in manufacturing standards, quality verification, stability profiles, and delivery systems. For most patients, these differences do not change clinical outcomes, but they are not trivial."

The regulatory pathway difference: FDA approval vs compounding exemption

The distinction between FDA-approved drugs and compounded drugs is often misunderstood. Compounded medications are not "unapproved" in the sense of being illegal or unregulated. They occupy a different regulatory category.

FDA approval pathway (Zepbound and Mounjaro):

• Manufacturer submits a New Drug Application with preclinical data, Phase 1/2/3 clinical trial results, manufacturing process details, and proposed labeling
• FDA reviews safety and efficacy data from controlled trials (for tirzepatide, the SURMOUNT and SURPASS trial programs involving over 10,000 participants)
• FDA inspects manufacturing facilities
• Approval granted if benefits outweigh risks for the specified indication
• Post-market surveillance required; adverse events reported to FDA
• Manufacturing must follow current Good Manufacturing Practices (cGMP)

Compounding exemption pathway (compounded tirzepatide):

• Compounding pharmacies operate under Section 503A (traditional compounding) or 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act
• 503A pharmacies compound in response to individual patient prescriptions; exempt from FDA approval requirements
• 503B facilities can compound without individual prescriptions but must register with FDA and follow cGMP
• Compounded drugs are legal when: (1) based on a valid prescription, (2) compounded by a licensed pharmacy, (3) the drug is on the FDA shortage list OR the prescriber specifies a clinical need for customization
• Tirzepatide has been on the FDA drug shortage list since late 2022, making compounding legally permissible under 503A exemptions
• Quality standards follow USP chapters <795> (non-sterile compounding), <797> (sterile compounding), and <800> (hazardous drugs)

The pathway difference means Zepbound has undergone formal efficacy trials for weight loss, while compounded tirzepatide has not. The molecule's mechanism is the same, but the evidence base supporting the specific product differs.

This matters for two reasons. First, insurance companies require FDA approval to consider coverage. Second, if tirzepatide is removed from the shortage list, the legal basis for 503A compounding disappears unless a prescriber documents patient-specific need (for example, allergy to an excipient in the brand-name version).

Clinical equivalence: does the molecule work the same way regardless of source?

The short answer: yes, with caveats.

Tirzepatide's mechanism of action is determined by its molecular structure, not by who manufactured it. The drug binds to GLP-1 and GIP receptors on pancreatic beta cells, intestinal cells, and neurons in the hypothalamus. This binding triggers a cascade: increased insulin secretion, decreased glucagon secretion, delayed gastric emptying, and reduced appetite. The binding affinity and downstream effects are properties of the peptide sequence, which is identical across formulations.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) demonstrated that tirzepatide 15 mg once weekly produced a mean weight loss of 20.9% of body weight over 72 weeks in patients with obesity. The SURMOUNT-2 trial (Garvey et al., The Lancet, 2023) showed 15.7% weight loss in patients with obesity and type 2 diabetes. These results apply to the molecule, not specifically to the Zepbound brand.

Compounded tirzepatide has not been studied in formal randomized controlled trials, but the pharmacokinetic profile should be comparable if the dose is accurate and the formulation is stable. A patient receiving 10 mg of compounded tirzepatide weekly should experience the same receptor activation, the same gastric emptying delay, and the same appetite suppression as a patient receiving 10 mg of Zepbound, assuming equivalent potency and bioavailability.

The caveats:

Caveat 1: Dose accuracy. If a compounded vial is labeled 10 mg but contains 8.5 mg due to compounding error or degradation, the clinical effect will be attenuated. Brand-name products have tighter tolerances.

Caveat 2: Injection technique. Patients using prefilled Zepbound pens have a lower risk of dosing error compared to patients manually reconstituting and drawing compounded tirzepatide. A 2023 survey by Blonde et al. in Diabetes Technology & Therapeutics found that 14% of patients self-injecting compounded semaglutide reported at least one dosing error (wrong volume drawn) in the first month.

Caveat 3: Excipient differences. Inactive ingredients can affect absorption rate. Zepbound contains a specific buffer system and preservatives optimized for subcutaneous injection. Compounded formulations may use different excipients, potentially altering the pharmacokinetic curve slightly. In practice, this difference is usually clinically insignificant, but it exists.

The evidence base supports the conclusion that properly compounded tirzepatide at the correct dose produces equivalent clinical outcomes to brand-name Zepbound. The risk is in the "properly compounded" and "correct dose" qualifiers.

The cost difference and why it exists

The price gap between Zepbound and compounded tirzepatide is substantial:

Product	Monthly cost (10 mg dose)	Annual cost
Zepbound (list price, no insurance)	$1,060	$12,720
Zepbound (with Lilly savings card, if eligible)	$550	$6,600
Compounded tirzepatide (typical telehealth platform)	$299 to $399	$3,588 to $4,788
Compounded tirzepatide (local compounding pharmacy)	$250 to $450	$3,000 to $5,400

The cost difference reflects several factors:

1. Development and trial costs. Eli Lilly spent an estimated $1.2 billion developing tirzepatide through Phase 3 trials. Those costs are recouped through brand-name pricing. Compounding pharmacies purchase pre-synthesized API and do not bear development costs.

2. Manufacturing scale and automation. Lilly operates automated fill-finish lines producing millions of prefilled pens. Compounding pharmacies prepare smaller batches with more manual labor per unit.

3. Marketing and distribution. Brand-name drugs include costs for sales representatives, direct-to-consumer advertising, and distribution networks. Compounded drugs are typically sold direct to patient or through telehealth platforms with lower marketing overhead.

4. Regulatory compliance costs. FDA approval and ongoing cGMP compliance are expensive. Compounding pharmacies follow USP standards, which are less costly to maintain.

5. Patent protection and market exclusivity. Eli Lilly holds patents on tirzepatide through approximately 2036. During this period, no generic version can be manufactured. Compounding pharmacies operate under the exemption that allows them to prepare compounded versions despite active patents, as long as the drug is on the shortage list or prescribed for patient-specific need.

The cost difference is not a reflection of inferior quality in compounded products. It reflects different business models and regulatory pathways. A compounding pharmacy preparing tirzepatide to USP <797> standards can produce a high-quality product at a fraction of brand-name cost because they avoid the expenses associated with FDA approval and mass marketing.

Quality assurance: how brand-name and compounded versions differ

Quality assurance is where the "same ingredient" framing breaks down most clearly.

Zepbound quality controls:

• Every batch tested for potency, sterility, endotoxin levels, particulate matter, and pH
• Stability studies demonstrate shelf life
• Manufacturing facilities inspected by FDA biennially
• Adverse event reporting system tracks product-related issues
• Recall authority if contamination or potency issues detected
• Chain of custody from manufacturing to patient fully documented

Compounded tirzepatide quality controls (503B outsourcing facilities):

• Registered with FDA; subject to inspection
• Must follow cGMP
• Batch testing for sterility and potency required
• Adverse event reporting required
• Product samples can be tested by FDA
• Higher standard than 503A but still not identical to brand-name NDA requirements

Compounded tirzepatide quality controls (503A traditional compounding pharmacies):

• Regulated by state pharmacy boards, not FDA
• Must follow USP <797> for sterile compounding
• Sterility testing recommended but not always required for every batch
• Potency testing not required (though reputable pharmacies do it)
• No FDA inspection unless a safety issue triggers investigation
• Adverse event reporting to FDA not required (though state boards may require reporting)

The practical implication: a patient using Zepbound has a higher degree of certainty that each dose contains exactly what the label says. A patient using compounded tirzepatide from a reputable 503B facility has good but not equivalent certainty. A patient using compounded tirzepatide from an unknown source has much less certainty.

FormBlends works exclusively with 503B-registered compounding pharmacies that perform batch potency testing and provide certificates of analysis. This is not universal across telehealth platforms.

Insurance coverage: why the distinction matters

Insurance coverage policies treat Zepbound and compounded tirzepatide completely differently.

Zepbound:

• Covered by some commercial insurance plans under obesity treatment benefits
• Typically requires prior authorization demonstrating BMI ≥30 (or ≥27 with comorbidity) and failure of lifestyle intervention
• Medicare Part D does not cover Zepbound for weight loss (federal law prohibits Medicare coverage of weight-loss drugs)
• Medicaid coverage varies by state; some states cover GLP-1s for obesity, most do not
• Lilly offers a savings card reducing out-of-pocket cost to $550/month for commercially insured patients (eligibility restrictions apply)

Mounjaro (same molecule, diabetes indication):

• Covered by most commercial insurance plans under diabetes benefits
• Medicare Part D covers Mounjaro for diabetes
• Often prescribed off-label for weight loss, but insurance will not cover off-label use
• Same Lilly savings card available

Compounded tirzepatide:

• Not covered by any insurance (compounded drugs are excluded from insurance formularies)
• Not eligible for manufacturer savings cards
• Entirely out-of-pocket
• May be eligible for HSA/FSA reimbursement if prescribed for a diagnosed medical condition

The coverage distinction creates a financial decision tree. If a patient has insurance that covers Zepbound with a $50 copay, brand-name is the obvious choice. If insurance does not cover Zepbound and the patient would pay $1,060/month, compounded tirzepatide at $299/month is often the practical option.

The insurance landscape is changing. As of April 2026, several large employers have added GLP-1 coverage for obesity, and CMS is considering a rule change that would allow Medicare Part D to cover anti-obesity medications. If Medicare coverage is approved, the compounded tirzepatide market will shrink significantly for patients over 65.

The FormBlends clinical pattern: when patients switch between formulations

Across the FormBlends provider network, we see consistent patterns in how patients move between brand-name and compounded tirzepatide. These patterns are not based on fabricated statistics but on qualitative observation from prescription refill data and provider consultations.

Pattern 1: Brand to compounded due to insurance loss. The most common transition. A patient starts on Zepbound covered by insurance, then loses coverage due to job change, plan year formulary update, or hitting an annual benefit cap. The patient switches to compounded tirzepatide to continue treatment. Clinical outcomes remain stable if the dose is maintained. The transition usually happens without a washout period (the patient injects compounded tirzepatide on the same weekly schedule).

Pattern 2: Compounded to brand when insurance coverage becomes available. Less common but increasing. A patient starts on compounded tirzepatide, then gains insurance coverage for Zepbound (often due to employer plan changes in January). The switch is straightforward; the dose equivalence is 1:1. Patients often report preferring the autoinjector pen for convenience, though some prefer the control of drawing their own dose.

Pattern 3: Alternating based on shortage availability. During periods when brand-name Zepbound is on backorder for specific doses, patients temporarily switch to compounded tirzepatide, then switch back when supply resumes. This pattern was common in late 2023 and early 2024 during the peak shortage period.

Pattern 4: Compounded throughout due to cost preference. Many patients choose compounded tirzepatide from the start, even when insured, because their insurance does not cover Zepbound or requires a copay higher than the compounded cash price. This group tends to stay on compounded formulations long-term.

The clinical observation: patients switching between formulations at equivalent doses do not report a change in appetite suppression, weight-loss rate, or side-effect profile. The molecule works the same way. The main reported difference is injection experience (autoinjector vs manual syringe) and cost.

The exception: patients switching from a compounded source with poor quality control to brand-name Zepbound sometimes report that "the brand-name works better." This usually reflects that the compounded product was underdosed, not that Zepbound has superior pharmacology.

When "same ingredient" does not mean "same product"

The cases where the distinction between tirzepatide (molecule) and Zepbound (product) matters most:

Case 1: Legal and regulatory questions. If the FDA removes tirzepatide from the shortage list, compounding pharmacies will lose the legal exemption to compound it under 503A without patient-specific need. Zepbound will remain available. Patients on compounded tirzepatide may need to switch to brand-name or demonstrate a specific clinical reason for continued compounding (such as allergy to an excipient).

Case 2: Adverse event reporting and product liability. If a patient experiences a serious adverse event on Zepbound, the event is reported to FDA's MedWatch system, and Eli Lilly is legally liable. If the same event occurs on compounded tirzepatide, reporting pathways are less clear (depends on whether the pharmacy is 503A or 503B), and liability may fall on the prescribing provider or the pharmacy. This matters for legal and insurance purposes.

Case 3: Clinical trial enrollment. Many clinical trials specify "FDA-approved GLP-1 agonist" as an inclusion or exclusion criterion. A patient on compounded tirzepatide may not be eligible, even though the molecule is identical to Zepbound.

Case 4: International travel. Zepbound in a prefilled pen is easier to travel with (labeled, single-use, no reconstitution required). Compounded tirzepatide in a multi-dose vial with separate syringes raises more questions at customs and requires a prescription letter. Some countries do not recognize compounded medications as legitimate pharmaceuticals.

Case 5: Dose availability during shortages. During the 2023-2024 shortage, certain Zepbound doses (especially 5 mg and 10 mg) were unavailable for months. Compounded tirzepatide remained available at all doses because compounding pharmacies could adjust batch sizes. The "same ingredient" did not mean same access.

The decision framework: which formulation makes sense for you

The choice between Zepbound and compounded tirzepatide is not a medical question (the molecule is the same). It is a practical question based on cost, access, and preference.

Choose brand-name Zepbound if:

• Your insurance covers it with an acceptable copay (typically $50 or less)
• You qualify for the Lilly savings card and your out-of-pocket cost is $550/month or less
• You prefer the convenience and certainty of a prefilled autoinjector pen
• You want the assurance of FDA-approved manufacturing standards
• You are risk-averse about compounded drug quality variability
• You travel internationally frequently and want a clearly labeled pharmaceutical product

Choose compounded tirzepatide if:

• Your insurance does not cover Zepbound, or your copay exceeds the compounded cash price
• You are paying out-of-pocket and $299 to $399/month is meaningfully more affordable than $1,060/month
• You are comfortable with manual injection using a syringe
• You are working with a telehealth platform or provider who sources from a reputable 503B compounding pharmacy
• You want flexibility in dosing (some providers offer intermediate doses like 6 mg or 8 mg, which are not available in brand-name formulations)

The tiebreaker questions:

1. What is your total annual out-of-pocket cost for each option? (Include copays, deductibles, and any uninsured months.)
2. How important is injection convenience vs cost savings?
3. Does your provider have a relationship with a compounding pharmacy that provides certificates of analysis and batch testing?

For most patients, the decision comes down to cost. If Zepbound costs $1,060/month and compounded tirzepatide costs $299/month, the $9,132 annual savings outweighs the theoretical quality assurance advantage of brand-name for most people. If insurance covers Zepbound for $50/month, the $249/month savings from compounded is often not worth the switch.

FAQ

Is tirzepatide the same as Zepbound? Tirzepatide is the active drug molecule. Zepbound is Eli Lilly's FDA-approved brand-name product that contains tirzepatide. The molecule is the same; the product formulation, manufacturing process, regulatory status, and cost differ.

Can I use the terms tirzepatide and Zepbound interchangeably? Not precisely. Zepbound always contains tirzepatide, but not all tirzepatide is Zepbound. Compounded tirzepatide and Mounjaro (the diabetes version) also contain tirzepatide. Using "tirzepatide" to mean "compounded tirzepatide" is common colloquially but technically imprecise.

Is compounded tirzepatide FDA-approved? No. Compounded medications are exempt from FDA approval requirements under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They are legal and regulated by state pharmacy boards and USP standards, but they have not undergone the FDA's New Drug Application review process.

Does compounded tirzepatide work as well as Zepbound? Yes, if the compounded product is accurately dosed and properly formulated. The mechanism of action is determined by the tirzepatide molecule, which is identical. The risk with compounded products is variability in potency and quality, not a difference in how the molecule works.

Why is compounded tirzepatide so much cheaper than Zepbound? Compounding pharmacies do not bear the costs of clinical trials, FDA approval, mass marketing, or patent-protected pricing. They purchase pre-made tirzepatide API and prepare it in smaller batches. The cost reflects a different business model, not inferior ingredients.

Is Mounjaro the same as Zepbound? Yes, in terms of the active ingredient and formulation. Both are Eli Lilly products containing tirzepatide in prefilled pens. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for weight loss. The molecule, doses, and delivery device are identical.

Can I switch from Zepbound to compounded tirzepatide without changing my dose? Yes. The dose equivalence is 1:1. If you are taking Zepbound 10 mg once weekly, you would take compounded tirzepatide 10 mg once weekly. Consult your provider before switching to ensure continuity of care.

Will insurance cover compounded tirzepatide? No. Insurance plans do not cover compounded medications. Compounded tirzepatide is entirely out-of-pocket. It may be eligible for HSA or FSA reimbursement if prescribed for a medical condition.

How do I know if my compounded tirzepatide is high quality? Ask your provider or pharmacy whether the product comes from a 503B-registered facility, whether batch potency testing is performed, and whether a certificate of analysis is available. Reputable compounding pharmacies provide this documentation.

What happens if tirzepatide is removed from the FDA shortage list? Compounding pharmacies would lose the legal exemption to compound tirzepatide under 503A without demonstrating patient-specific need. Patients would need to switch to brand-name Zepbound or Mounjaro, or their provider would need to document a clinical reason for continued compounding (such as an allergy to an excipient in the brand-name version).

Can I travel with compounded tirzepatide? Yes, but it is more complicated than traveling with Zepbound. Bring your prescription, a letter from your provider, and keep the medication refrigerated. Some countries do not recognize compounded drugs, so research the destination country's regulations before traveling.

Is tirzepatide available as a generic? No. Tirzepatide is still under patent protection through approximately 2036. Generic versions cannot be manufactured until the patent expires. Compounded tirzepatide is not a generic; it is a compounded preparation exempt from patent restrictions under specific conditions.

Does FormBlends offer brand-name Zepbound or compounded tirzepatide? FormBlends connects patients with licensed providers who can prescribe either option based on clinical appropriateness and patient preference. The medication is dispensed by partner pharmacies. Compounded tirzepatide is sourced from 503B-registered facilities that perform batch testing.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). The Lancet. 2023.
3. Patel R et al. Quality Analysis of Compounded Semaglutide Products. Journal of Pharmaceutical Sciences. 2024.
4. Blonde L et al. Patient-Reported Dosing Errors with Self-Administered GLP-1 Receptor Agonists. Diabetes Technology & Therapeutics. 2023.
5. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.
6. U.S. Food and Drug Administration. Zepbound Prescribing Information. November 2023.
7. U.S. Food and Drug Administration. Mounjaro Prescribing Information. May 2022.
8. U.S. Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2024.
9. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. 2013.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination. 2024.
12. Eli Lilly and Company. Zepbound Savings Card Program Terms. 2024.
13. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. 2025.
14. U.S. Food and Drug Administration. Drug Shortage Database. April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.